Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.

导出 LinkOut

翻译打印收藏纠错

作者： Kotaro,Shirakawa ^[1] ; Lan,Wang ^[2] ; Na,Man ^[3] ; Jasna,Maksimoska ^[4] ; Alexander W,Sorum ^[5] ; Hyung W,Lim ^[6] ; Intelly S,Lee ^[5] ; Tadahiro,Shimazu ^[6] ; John C,Newman ^[7] ; Sebastian,Schröder ^[8] ; Melanie,Ott ^[9] ; Ronen,Marmorstein ^[1] ; Jordan,Meier ^[2] ; Stephen,Nimer ^[1] ; Eric,Verdin ^[2]

作者单位： Gladstone Institutes, University of California, San Francisco, United States. ^[1] Department of Medicine, University of California, San Francisco, United States. ^[2] Department of Hematology and Oncology, Kyoto University, Kyoto, Japan. ^[3] Graduate School of Medicine, Kyoto University, Kyoto, Japan. ^[4] University of Miami, Gables, United States. ^[5] Sylvester Comprehensive Cancer Center, Miami, United States. ^[6] Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States. ^[7] Department of Biochemistry and Biophysics, Abramson Family Cancer Research Institute, Philadelphia, United States. ^[8] Chemical Biology Laboratory, National Cancer Institute, Frederick, United States. ^[9]

关键词 acetylation diflunisal histone acetyltransferase human biology medicine salicylate